期刊
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
卷 15, 期 8, 页码 941-947出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/17474124.2021.1884544
关键词
Pancreatic cancer; pancreatic exocrine insufficiency; pancreatic Enzyme Replacement Therapy; survival; weight
This study analyzed four RCTs and found that the use of PERT in APC patients did not significantly affect OS, weight change, or quality of life. However, due to non-uniform designs, different endpoints, and a smaller number of patients, more RCTs are needed to support routine use of PERT in APC.
Objectives: We analyzed randomized controlled trials (RCTs) to assess the impact of PERT on weight change, quality of life, and overall survival (OS) in patients with advanced pancreatic cancer (APC). Methods: All RCTs indexed in PubMed, Medline and Scopus, databases reporting PEI in APC and the effect of PERT were included up to August 2020. The primary outcome measure was OS and the secondary outcome measures were weight change and quality of life. Results: Four RCTs including 194 patients (107 males) were analyzed. Ninety-eight (50.5%) patients received PERT treatment. Treatment with PERT did not show a significant effect on OS (SMD 0.12, 95% confidence interval -0.46-0.70, p = 0.46). There was no difference in change in body weight (SMD 0.53, 95% confidence interval -0.72-1.77, p = 0.21). Quality of life was not significantly different in those taking PERT compared to controls. Conclusions: This meta-analysis found no significant difference in OS, change in weight or quality of life with use of PERT in APC. However, non-uniform designs and different end points , along with smaller number of patients, limit a more in-depth analysis of outcomes. Further, RCTs are warranted to support evidence of routine use of PERT in APC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据